MYNERVA AG Company Profile

Background

Overview:
MYNERVA AG, founded in 2023, is a privately held medical technology company headquartered in Zurich, Switzerland. The company specializes in developing therapeutic devices aimed at alleviating diabetic neuropathy symptoms, with a mission to restore sensation and reduce pain in affected patients. By focusing on non-invasive nerve stimulation, MYNERVA seeks to enhance patient quality of life and reduce the risk of falls associated with diabetic neuropathy.

Key Strategic Focus

Core Objectives:
MYNERVA's primary objective is to provide innovative, non-invasive solutions for managing diabetic neuropathy. The company emphasizes the development of therapeutic devices that offer pleasant nerve stimulation to decrease nerve pain and improve patient mobility.

Areas of Specialization:
The company specializes in therapeutic devices within the digital health and HealthTech sectors, focusing on diabetic neuropathy treatment.

Key Technologies Utilized:
MYNERVA employs proprietary non-invasive nerve stimulation technologies designed to restore sensation and reduce pain in diabetic neuropathy patients.

Primary Markets Targeted:
The company targets the healthcare market, specifically addressing the needs of patients suffering from diabetic neuropathy.

Financials and Funding

Funding History:
Since its inception, MYNERVA has participated in multiple accelerator and incubator programs, securing funding to support its development initiatives.

Recent Funding Rounds:

Accelerator/Incubator (November 15, 2023): Completed.

Accelerator/Incubator (September 26, 2023): Completed, raising $33.6K.

Grant (May 31, 2023): Completed, raising $26.8K.

Notable Investors:

DCB Innovation

Future of Health Grant

Swiss Innovation Challenge

BlueLion Incubator

Utilization of Capital:
The funds raised are intended to advance the development and commercialization of MYNERVA's therapeutic devices, focusing on product development, clinical trials, and market entry strategies.

Pipeline Development

Key Pipeline Candidates:

Therapeutic Device for Diabetic Neuropathy: Currently in the development phase, this device aims to restore sensation and reduce pain through non-invasive nerve stimulation.

Stages of Development:

The device is undergoing clinical validation to ensure efficacy and safety.

Target Conditions:

Diabetic neuropathy.

Timelines for Anticipated Milestones:

Specific timelines for clinical trials and product launch have not been publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies:

MYNERVA has developed a non-invasive nerve stimulation platform designed to decrease nerve pain and reduce falls in diabetic neuropathy patients.

Significant Scientific Methods:

The company employs advanced neurostimulation techniques to achieve therapeutic outcomes.

Leadership Team

Key Executive Profiles:

Greta Preatoni: Co-Founder & Chief Executive Officer.

Luigi Carotenuto: Chief Technology Officer & Technical Lead.

Giacomo Valle: Co-Founder.

Professional Backgrounds:

The leadership team comprises professionals with expertise in engineering, neuroscience, and rehabilitation, contributing to the development of innovative therapeutic solutions.

Key Contributions:

The team has been instrumental in advancing MYNERVA's mission to provide non-invasive treatments for diabetic neuropathy.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within MYNERVA's leadership team.

Competitor Profile

Market Insights and Dynamics:

The therapeutic devices market, particularly for diabetic neuropathy, is experiencing growth due to increasing prevalence of diabetes and associated complications.

Competitor Analysis:

While specific competitors in the diabetic neuropathy device sector are not detailed, MYNERVA operates in a competitive landscape with other companies developing therapeutic devices for similar conditions.

Strategic Collaborations and Partnerships

MYNERVA has engaged with several accelerator and incubator programs, including DCB Innovation, Future of Health Grant, Swiss Innovation Challenge, and BlueLion Incubator, to strengthen its market position and innovation capacity.